Product: Cytochrome C Antibody
Catalog: AF0146
Description: Rabbit polyclonal antibody to Cytochrome C
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
Mol.Wt.: 15kDa; 12kD(Calculated).
Uniprot: P99999
RRID: AB_2833328

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Zebrafish(88%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
Cytochrome C Antibody detects endogenous levels of total Cytochrome C.
RRID:
AB_2833328
Cite Format: Affinity Biosciences Cat# AF0146, RRID:AB_2833328.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CYC; CYC_HUMAN; CYCS; Cytochrome c; Cytochrome c somatic; HCS; THC4;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Description:
CYCS Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain. Belongs to the cytochrome c family.
Sequence:
MGDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSYTAANKNKGIIWGEDTLMEYLENPKKYIPGTKMIFVGIKKKEERADLIAYLKKATNE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Xenopus
100
Rabbit
100
Zebrafish
88
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P99999 As Substrate

Site PTM Type Enzyme
G2 Acetylation
K9 Acetylation
K28 Sumoylation
K28 Ubiquitination
T29 Phosphorylation
K40 Ubiquitination
T41 Phosphorylation
Y47 Phosphorylation
S48 Phosphorylation
Y49 Phosphorylation
T50 Phosphorylation
K54 Ubiquitination
Y68 Phosphorylation
K73 Acetylation
K73 Ubiquitination
K74 Acetylation
K74 Ubiquitination
Y75 Phosphorylation
T79 Phosphorylation
K80 Ubiquitination
K87 Acetylation
K87 Ubiquitination
K88 Acetylation
K89 Acetylation
Y98 Phosphorylation
K100 Acetylation
K100 Methylation
K100 Ubiquitination
K101 Methylation

Research Backgrounds

Function:

Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain.

Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members of the Bcl-2 family leads to altered mitochondrial membrane permeability resulting in release of cytochrome c into the cytosol. Binding of cytochrome c to Apaf-1 triggers the activation of caspase-9, which then accelerates apoptosis by activating other caspases.

PTMs:

Binds 1 heme group per subunit.

Phosphorylation at Tyr-49 and Tyr-98 both reduce by half the turnover in the reaction with cytochrome c oxidase, down-regulating mitochondrial respiration.

Subcellular Location:

Mitochondrion intermembrane space.
Note: Loosely associated with the inner membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Family&Domains:

Belongs to the cytochrome c family.

Research Fields

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis - multiple species.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Parkinson's disease.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Neurodegenerative diseases > Huntington's disease.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cardiovascular diseases > Viral myocarditis.

· Metabolism > Energy metabolism > Sulfur metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

References

1). Synthesis of hydroxycinnamic acid derivatives as mitochondria-targeted antioxidants and cytotoxic agents. Acta Pharmaceutica Sinica B (PubMed: 28119815) [IF=14.5]

Application: WB    Species: Human    Sample:

Figure 7 Detection of cyt c release from energized mitochondria suspensions (2 mg protein/mL). (A) In the presence of 10 μmol/L MitoHCAs. a: control; b: MitoCaA; c: MitoFA; d: Mitop-CoA; e: MitoCA. (B) a: control; b: 1 μmol/L MitoCaA; c: 20 μmol/L MitoCaA +1 μmol/L CsA; d: 20 μmol/L MitoCaA. The blots shown are representative of three independent experiments demonstrating similar results. (C) In the presence of the various concentrations of MitoCaA. (D) In the presence of MitoHCAs, CaA and butylTPP (10 μmol/L) with or without Ca2+. The quantitative assays were performed by the dithionite-reduction method. The values represent mean±SEM of three independent experiments. ***P

2). Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. CANCER LETTERS (PubMed: 31904482) [IF=9.7]

3). Iron induces B cell pyroptosis through Tom20–Bax–caspase–gasdermin E signaling to promote inflammation post-spinal cord injury. Journal of Neuroinflammation (PubMed: 37480037) [IF=9.3]

Application: WB    Species: Mouse    Sample: B cells

Fig. 3 Pyroptosis induced by iron accumulation may occur in splenic B cells after SCI. a Three days after SCI, serum samples were collected for quantification of the protein expression levels of MCP-1, IL-1β, IL-6, and TNF-α by ELISA. b Three days after SCI, injured spinal cord homogenates were collected for quantification of the protein expression levels of MCP-1, IL-1β, IL-6, and TNF-α by ELISA. c Three days after SCI, the spleen was stained with Prussian blue to detect the level of iron ion. d Three days after SCI, serum samples were collected to quantify the concentration of iron ions. e Three days after SCI, B cell lysates were collected to quantify the concentration of iron ions. f Detection of Tom20-Bax-caspase-GSDME pathway-related protein expression in B cells by western blot. g The knock-down efficiency of AAV on Tom20 in B cells was verified. h, l, m The expression levels of MCP-1, IL-1 β, IL-6, TNF- α, IgG and IgM in serum of different groups were detected by ELISA. i–k Three days after SCI, the spleens of mice were observed, and the spleen length and organ index of different groups were compared. n, o, q The spleen was taken for HE staining, Prussian blue staining, and immunofluorescence. CD19+ was red, dapi was blue, and merge was combined. p Detection of nerve evoked potentials in different groups of mice. r Detection of the expression of Tom20-Bax-caspsae-GSDME pathway-related proteins in different groups of B cells. All data are expressed as the mean ± SD (n ≥ 3 replicates per group). ns P > 0.05, * P 

4). The anti-hepatocellular carcinoma effect of Brucea javanica oil in ascitic tumor-bearing mice: The detection of brusatol and its role. Biomedicine & Pharmacotherapy (PubMed: 33341052) [IF=7.5]

5). Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cells. BIOMEDICINE & PHARMACOTHERAPY (PubMed: 28363167) [IF=7.5]

Application: WB    Species: human    Sample:

Fig. 2. Effects of CsA on emodin-induced apoptosis. The cells were treated with emodin for 48 h in the presence or absence of CsA (5mM), then assays were performed. (A) Analysis of apoptosis by nuclear condensation. The Hoechst 33342 staining showed typical apoptotic morphology changes after emodin treatment. The images were acquired by inverted fluorescence microscopy. (B) Analysis of apoptosis by Annexin V/PI double-staining assay. (C) Determination of Cyto-C level in mitochondria and cytosol by western blots. b-actin and VDAC1 were used as internal control.

6). Edaravone combined with dexamethasone exhibits synergic effects on attenuating smoke-induced inhalation lung injury in rats. Biomedicine & Pharmacotherapy (PubMed: 34225014) [IF=7.5]

7). Proteus mirabilis Vesicles Induce Mitochondrial Apoptosis by Regulating miR96-5p/Abca1 to Inhibit Osteoclastogenesis and Bone Loss. Frontiers in Immunology (PubMed: 35242136) [IF=7.3]

Application: WB    Species: mouse    Sample: Osteoclasts

FIGURE 4 | Effect of P.M OMVs on mitochondria-dependent osteoclast apoptosis.(J) Cyto c expression in the cytoplasm and mitochondria with or without P.M OMV treatment. Data were obtained from three independent experiments and represented as mean ± SD. ####p < 0.0001 compared to M-CSF. *p < 0.05; **p < 001; ***p < 0.001; ****p < 0.0001 compared to M-CSF + RANKL. ns, not significant.

Application: WB    Species: Mouse    Sample: osteoclasts

Figure 4 Effect of P.M OMVs on mitochondria-dependent osteoclast apoptosis. (A) Venn diagram showing the intersection of negatively correlated miRNA–mRNA pairs within miRNA and mRNA sequences. (B) KEGG enrichment analysis of upregulated genes is shown in the bubble chart. The top 15 genes significantly enriched in the KEGG pathway (p < 0.05) are presented. Changes in osteoclast (C, D) apoptosis, (E, F) intracellular ROS, and (G, H) mitochondrial membrane potential level after being cultured with or without 0.15 or 0.3 μg/ml of P.M OMVs for 5 days. (I) Western blot analysis of caspase-3, Bcl-2, and Bax. (J) Cyto c expression in the cytoplasm and mitochondria with or without P.M OMV treatment. Data were obtained from three independent experiments and represented as mean ± SD. ####p < 0.0001 compared to M-CSF. *p < 0.05; **p < 001; ***p < 0.001; ****p < 0.0001 compared to M-CSF + RANKL. ns, not significant.

8). Lactoferrin ameliorates pathological cardiac hypertrophy related to mitochondrial quality control in aged mice. Food & Function (PubMed: 34223567) [IF=6.1]

Application: WB    Species: Mice    Sample:

Fig. 2 LF inhibited mitochondria-dependent apoptosis of myocardium in aged mice. (A) Representative images of the TUNEL assay. (B) Quantification of TUNEL-positive nuclei. (C) Representative immunoblotting images of relative protein expression. (D)–(I) Quantification of relative protein expression involved in mitochondria-dependent apoptosis; *P < 0.05 and **P < 0.01 vs. 2-month group; #P < 0.05 and ##P < 0.01 vs. 16-month group.

9). Inhibition of microRNA-327 ameliorates ischemia/reperfusion injury-induced cardiomyocytes apoptosis through targeting apoptosis repressor with caspase recruitment domain. JOURNAL OF CELLULAR PHYSIOLOGY (PubMed: 31587299) [IF=5.6]

Application: WB    Species: rat    Sample: heart

FIGURE 7| Inhibition of miR‐327 suppressed I/R‐induced extrinsic and intrinsic apoptosis‐associated molecules expression. Caspase‐8, Fas and FasL protein expression was detected in heart tissues of MI/RI rats by western blot (a). Quantitative analysis of Caspase‐8 (b), Fas (c), and FasL(d) expression was shown in Bar graphs.Caspase‐9, Bax, Bcl‐2, and Cyt‐c proteinexpression was detected in heart tissues of MI/RI rats by Western blot (e).

10). Akkermansia muciniphila Aspartic Protease Amuc_1434* Inhibits Human Colorectal Cancer LS174T Cell Viability via TRAIL-Mediated Apoptosis Pathway. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (PubMed: 32403433) [IF=5.6]

Application: WB    Species: human    Sample: LS174T cells

Figure 5. | Amuc_1434* mediated the activation of the apoptosis pathway in LS174T cells.(B) Amuc_1434* indirectly affected the expression of proteins in the mitochondrial apoptosis pathway.(a) B-cell lymphoma-2 interacting-domain death agonist (Bid), B-cell lymphoma-2-Associated X Protein(Bax), B-cell lymphoma-2 (Bcl-2), Cytochrome c (CytC), and Endonuclease G (EndoG) proteins of LS174T cells were detected using Western blot analysis after treatment with Amuc_1434* for 24 h.β-actin was used as the loading control.

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.